8-K: Tenax Therapeutics Faces Nasdaq Delisting Notice and Appoints Interim CFO

Tenax Therapeutics received a delisting notice from Nasdaq due to insufficient publicly held shares and appointed an interim CFO following the passing of the previous CFO.

Summary

• Tenax Therapeutics received a notification from Nasdaq on January 11, 2024, stating they no longer meet the minimum requirement of 500,000 publicly held shares.
• This non-compliance is a result of a 1-for-80 reverse stock split that was implemented on January 2, 2024.
• The company has until February 26, 2024, to submit a plan to Nasdaq to regain compliance.
• There is no guarantee that Tenax will be able to meet the requirements or maintain its listing on the Nasdaq Capital Market.
• On January 9, 2024, Lawrence R. Hoffman was appointed as Interim Chief Financial Officer, effective January 11, 2024.
• Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023.
• Mr. Hoffman will be compensated at a rate of $416 per hour through a consulting agreement with Danforth Advisors, LLC.

Sentiment

Score: 3

Explanation: The document contains negative news regarding a delisting notice and the passing of the previous CFO, offset slightly by the appointment of an interim CFO. The overall sentiment is negative due to the uncertainty surrounding the company's future on the Nasdaq.

Positives

• The company has a period until February 26, 2024 to submit a plan to Nasdaq to regain compliance.
• The appointment of an experienced interim CFO provides stability to the company's financial operations.

Negatives

• The company is in non-compliance with Nasdaq listing rules regarding minimum publicly held shares.
• There is no assurance that the company will be able to regain compliance and maintain its Nasdaq listing.
• The company had to appoint an interim CFO due to the passing of the previous CFO.

Risks

• There is a risk that Tenax may be delisted from the Nasdaq Capital Market if it fails to regain compliance.
• The company's stock price could be negatively impacted by the delisting notice.
• The company's financial operations could be impacted by the transition to a new CFO.

Future Outlook

Tenax intends to consider options to achieve compliance with Nasdaq listing rules and submit a plan to Nasdaq by February 26, 2024. There is no assurance that they will be successful.

Management Comments

• The company intends to consider options available to achieve compliance with the Nasdaq listing rules.
• The company will provide its plan to Nasdaq by February 26, 2024.

Industry Context

Delisting notices are not uncommon for companies that have undergone reverse stock splits, especially if the split does not result in the required number of publicly held shares. The appointment of an interim CFO is a common practice to ensure continuity in financial operations during a transition period.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly after reverse stock splits.
• The appointment of an interim CFO through a consulting firm like Danforth Advisors is a common practice in the biotech industry to fill temporary leadership gaps.
• SCYNEXIS, Inc. (Nasdaq: SCYX), where Mr. Hoffman previously served as Interim CFO, is a comparable company in the biotech sector that has also utilized consulting services for financial leadership.

Management Changes

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Tenax will develop a plan to regain compliance with Nasdaq listing rules.
• Tenax will submit the plan to Nasdaq by February 26, 2024.
• Nasdaq will review the plan and provide a decision.

Key Dates

Keywords

delisting, Nasdaq, compliance, reverse stock split, interim CFO, financial officer, publicly held shares, Danforth Advisors